Logo image of ANIK

ANIKA THERAPEUTICS INC (ANIK) Stock Fundamental Analysis

NASDAQ:ANIK - Nasdaq - US0352551081 - Common Stock - Currency: USD

14.03  +0.01 (+0.07%)

After market: 14.03 0 (0%)

Fundamental Rating

4

Taking everything into account, ANIK scores 4 out of 10 in our fundamental rating. ANIK was compared to 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ANIK as it has an excellent financial health rating, but there are worries on the profitability. ANIK is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ANIK has reported negative net income.
In the past year ANIK had a positive cash flow from operations.
ANIK had negative earnings in 4 of the past 5 years.
Of the past 5 years ANIK 4 years had a positive operating cash flow.
ANIK Yearly Net Income VS EBIT VS OCF VS FCFANIK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M -80M

1.2 Ratios

The Return On Assets of ANIK (-27.81%) is better than 70.07% of its industry peers.
The Return On Equity of ANIK (-36.62%) is better than 72.89% of its industry peers.
Industry RankSector Rank
ROA -27.81%
ROE -36.62%
ROIC N/A
ROA(3y)-20.88%
ROA(5y)-13.6%
ROE(3y)-26.93%
ROE(5y)-17.63%
ROIC(3y)N/A
ROIC(5y)N/A
ANIK Yearly ROA, ROE, ROICANIK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

ANIK has a better Gross Margin (61.75%) than 78.35% of its industry peers.
In the last couple of years the Gross Margin of ANIK has declined.
The Profit Margin and Operating Margin are not available for ANIK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.43%
GM growth 5Y-3.15%
ANIK Yearly Profit, Operating, Gross MarginsANIK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

ANIK does not have a ROIC to compare to the WACC, probably because it is not profitable.
ANIK has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, ANIK has more shares outstanding
There is no outstanding debt for ANIK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANIK Yearly Shares OutstandingANIK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
ANIK Yearly Total Debt VS Total AssetsANIK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ANIK has an Altman-Z score of 4.14. This indicates that ANIK is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 4.14, ANIK belongs to the best of the industry, outperforming 80.11% of the companies in the same industry.
ANIK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.14
ROIC/WACCN/A
WACC10.2%
ANIK Yearly LT Debt VS Equity VS FCFANIK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

A Current Ratio of 4.88 indicates that ANIK has no problem at all paying its short term obligations.
ANIK has a Current ratio of 4.88. This is comparable to the rest of the industry: ANIK outperforms 54.23% of its industry peers.
ANIK has a Quick Ratio of 3.85. This indicates that ANIK is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ANIK (3.85) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.88
Quick Ratio 3.85
ANIK Yearly Current Assets VS Current LiabilitesANIK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 61.74% over the past year.
The Revenue has decreased by -8.92% in the past year.
ANIK shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.91% yearly.
EPS 1Y (TTM)61.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.12%
Revenue 1Y (TTM)-8.92%
Revenue growth 3Y-6.73%
Revenue growth 5Y0.91%
Sales Q2Q%-28.78%

3.2 Future

ANIK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.24% yearly.
Based on estimates for the next years, ANIK will show a quite strong growth in Revenue. The Revenue will grow by 11.88% on average per year.
EPS Next Y70.93%
EPS Next 2Y40.49%
EPS Next 3Y23.03%
EPS Next 5Y28.24%
Revenue Next Year-25.1%
Revenue Next 2Y-9.76%
Revenue Next 3Y-5.05%
Revenue Next 5Y11.88%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ANIK Yearly Revenue VS EstimatesANIK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
ANIK Yearly EPS VS EstimatesANIK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ANIK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANIK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANIK Price Earnings VS Forward Price EarningsANIK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ANIK is valued cheaper than 92.78% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 50.17
ANIK Per share dataANIK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

ANIK's earnings are expected to grow with 23.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.49%
EPS Next 3Y23.03%

More info and screens

0

5. Dividend

5.1 Amount

ANIK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANIKA THERAPEUTICS INC

NASDAQ:ANIK (4/21/2025, 4:38:30 PM)

After market: 14.03 0 (0%)

14.03

+0.01 (+0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12 2025-03-12/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners87.43%
Inst Owner Change0.08%
Ins Owners2.88%
Ins Owner Change3.84%
Market Cap198.95M
Analysts87.5
Price Target24.48 (74.48%)
Short Float %2.64%
Short Ratio5.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-966.25%
Min EPS beat(2)-1533.99%
Max EPS beat(2)-398.5%
EPS beat(4)0
Avg EPS beat(4)-529.08%
Min EPS beat(4)-1533.99%
Max EPS beat(4)-62.81%
EPS beat(8)1
Avg EPS beat(8)-457.25%
EPS beat(12)4
Avg EPS beat(12)-299.66%
EPS beat(16)7
Avg EPS beat(16)-179.68%
Revenue beat(2)1
Avg Revenue beat(2)-3.13%
Min Revenue beat(2)-9.72%
Max Revenue beat(2)3.46%
Revenue beat(4)2
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-9.72%
Max Revenue beat(4)3.46%
Revenue beat(8)5
Avg Revenue beat(8)0.96%
Revenue beat(12)9
Avg Revenue beat(12)2.31%
Revenue beat(16)13
Avg Revenue beat(16)3.55%
PT rev (1m)0%
PT rev (3m)-9.43%
EPS NQ rev (1m)-24.63%
EPS NQ rev (3m)-218.51%
EPS NY rev (1m)-195%
EPS NY rev (3m)-195%
Revenue NQ rev (1m)2.06%
Revenue NQ rev (3m)-0.21%
Revenue NY rev (1m)-1.75%
Revenue NY rev (3m)-1.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.31
P/FCF N/A
P/OCF 36.82
P/B 1.29
P/tB 1.38
EV/EBITDA 50.17
EPS(TTM)-2.07
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)0.38
OCFY2.72%
SpS10.71
BVpS10.86
TBVpS10.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.81%
ROE -36.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.75%
FCFM N/A
ROA(3y)-20.88%
ROA(5y)-13.6%
ROE(3y)-26.93%
ROE(5y)-17.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.43%
GM growth 5Y-3.15%
F-Score6
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 102.62%
Cap/Sales 5.49%
Interest Coverage N/A
Cash Conversion 189.31%
Profit Quality N/A
Current Ratio 4.88
Quick Ratio 3.85
Altman-Z 4.14
F-Score6
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)64.17%
Cap/Depr(5y)48.11%
Cap/Sales(3y)5.41%
Cap/Sales(5y)4.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.12%
EPS Next Y70.93%
EPS Next 2Y40.49%
EPS Next 3Y23.03%
EPS Next 5Y28.24%
Revenue 1Y (TTM)-8.92%
Revenue growth 3Y-6.73%
Revenue growth 5Y0.91%
Sales Q2Q%-28.78%
Revenue Next Year-25.1%
Revenue Next 2Y-9.76%
Revenue Next 3Y-5.05%
Revenue Next 5Y11.88%
EBIT growth 1Y72.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year126.54%
EBIT Next 3Y33.18%
EBIT Next 5Y36.1%
FCF growth 1Y59.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y402.18%
OCF growth 3Y-13.68%
OCF growth 5Y-31.94%